Evidence map›Paper›PMID 35699798›Full record

SynthesisCancer causes & control : CCC2022

Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review.

Elliott Freudenburg, Iyla Bagheri, Sunay Srinivas, Ariza Martinez, Nagireddy Putluri, Zachary Klaassen, Ashish M Kamat, Badrinath R Konety, William Y Kim, Lars Dyrskjøt and 6 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Cancer causes & control : CCC, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 12 institutions in 4 countries.

Elliott FreudenburgDepartment of Surgery, Division of Urology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA.
Iyla BagheriDepartment of Surgery, Division of Urology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA.
Sunay SrinivasDepartment of Surgery, Division of Urology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA.
Ariza MartinezDepartment of Surgery, Division of Urology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA.
Nagireddy PutluriDepartment of Molecular and Cellular Biology, Dan L. Duncan Cancer Center, Advanced Technology Core, Alkek Center for Molecular Discovery, Baylor College of Medicine, Houston, TX, USA.
Zachary KlaassenDepartment of Surgery, Section of Urology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Ashish M KamatDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Badrinath R KonetyVirginia Piper Cancer Center and Piper Breast Centers, Allina Health Cancer Institute, Minneapolis, MN, USA.
William Y KimDivision of Hematology/Oncology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Lars DyrskjøtDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
David J McConkeyJohns Hopkins Greenberg Bladder Cancer Institute, Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
Stephen J FreedlandDepartment of Urology, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Peter C BlackDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Siamak DaneshmandDepartment of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
James W F CattoAcademic Urology Unit, University of Sheffield, Sheffield, UK.
Stephen B WilliamsDepartment of Surgery, Division of Urology, The University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555, USA. stbwilli@utmb.edu.ORCID http://orcid.org/0000-0002-2683-2185
The University of Texas Medical Branch at Galveston · USAarhus University Hospital · DKAllina Health · USAugusta University · USBaylor College of Medicine · USCedars-Sinai Medical Center · USJohns Hopkins University · USThe University of Texas MD Anderson Cancer Center · USUniversity of British Columbia · CAUniversity of North Carolina at Chapel Hill · USUniversity of Sheffield · GBUniversity of Southern California · US

Funding

Identify the DNA Adduct and Associated Metabolic Alterations in Bladder Cancer of SmokersR01CA216426 · NCI · BAYLOR COLLEGE OF MEDICINE · PI EL-ZEIN, RANDA A, PUTLURI, NAGIREDDY · 2018 to 2022
$2.0M
Racial Disparity in Bladder Cancer and Identification of Altered Metabolism in African American Compare to European Bladder CancerR01CA220297 · NCI · BAYLOR COLLEGE OF MEDICINE · PI PUTLURI, NAGIREDDY · 2017 to 2021
$1.8M
NCI NIH HHS R01 CA216426NCI NIH HHS R01 CA220297
6 · The paper itself

Abstract

purposeTo systematically review the literature to investigate racial disparities among bladder cancer clinical trial enrollees.

methodsA systematic review was conducted using Ovid, MEDLINE® to identify clinical trials between 1970 and 2020. Articles were reviewed and were included if they assessed race in their outcomes reporting among bladder cancer patients enrolled in clinical trials. The review was conducted in accordance with the PRISMA statement.

resultsWe identified 544 clinical trials meeting our initial search criteria, with only 24 (4.4%) studies reporting racial demographic data. Enrollees were largely Caucasian (81-98%), with a strikingly small proportion of enrolled patients consisting of African-Americans (2-8%) and Hispanics (2-5%). Only one of the studies reported results on the efficacy and safety/tolerability of the tested treatment separately for racial groups and performed analyses stratified by race.

conclusionRace is poorly studied in bladder cancer clinical trials. Trial cohorts may not reflect multicultural populations. The potential association between race and efficacy, safety or tolerability of the tested interventions is unknown. Given the up to twofold increase in bladder cancer-specific death among African-Americans, further research is needed to address the impact of race in clinical trials, while encompassing socioeconomic factors and disease risk factor exposures.

Indexed as

Urinary Bladder NeoplasmsBlack or African AmericanHispanic or LatinoHumansRacial GroupsWhite PeopleBladder CancerClinical TrialsDisparitiesRaceReporting

Identifiers

PMID35699798
OpenAlexW4282821641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.